Literature DB >> 17976162

Expression, binding, and signaling properties of CRF2(a) receptors endogenously expressed in human retinoblastoma Y79 cells: passage-dependent regulation of functional receptors.

Eric Gutknecht1, Richard L Hauger, Ilse Van der Linden, Georges Vauquelin, Frank M Dautzenberg.   

Abstract

Endogenous expression of the corticotropin-releasing factor type 2a receptor [CRF2(a)] but not CRF2(b) and CRF2(c) was observed in higher passage cultures of human Y79 retinoblastoma cells. Functional studies further demonstrated an increase in CRF2(a) mRNA and protein levels with higher passage numbers (> 20 passages). Although the CRF1 receptor was expressed at higher levels than the CRF2(a) receptor, both receptors were easily distinguishable from one another by selective receptor ligands. CRF(1)-preferring or non-selective agonists such as CRF, urocortin 1 (UCN1), and sauvagine stimulated cAMP production in Y79 to maximal responses of approximately 100 pmoles/10(5) cells, whereas the exclusive CRF2 receptor-selective agonists UCN2 and 3 stimulated cAMP production to maximal responses of approximately 25-30 pmoles/10(5) cells. UCN2 and 3-mediated cAMP stimulation was potently blocked by the approximately 300-fold selective CRF2 antagonist antisauvagine (IC50 = 6.5 +/- 1.6 nmol/L), whereas the CRF(1)-selective antagonist NBI27914 only blocked cAMP responses at concentrations > 10 microL. When the CRF(1)-preferring agonist ovine CRF was used to activate cAMP signaling, NBI27914 (IC50 = 38.4 +/- 3.6 nmol/L) was a more potent inhibitor than antisauvagine (IC50 = 2.04 +/- 0.2 microL). Finally, UCN2 and 3 treatment potently and rapidly desensitized the CRF2 receptor responses in Y79 cells. These data demonstrate that Y79 cells express functional CRF1 and CRF2a receptors and that the CRF2(a) receptor protein is up-regulated during prolonged culture.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976162      PMCID: PMC3102762          DOI: 10.1111/j.1471-4159.2007.05052.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  50 in total

Review 1.  CRF and CRF receptors: role in stress responsivity and other behaviors.

Authors:  Tracy L Bale; Wylie W Vale
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

2.  Molecular cloning and functional expression of the mouse CRF2(a) receptor splice variant.

Authors:  Frank M Dautzenberg; Jacqueline Higelin; Sandra Wille; Olaf Brauns
Journal:  Regul Pept       Date:  2004-09-15

3.  Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors.

Authors:  N Vita; P Laurent; S Lefort; P Chalon; J M Lelias; M Kaghad; G Le Fur; D Caput; P Ferrara
Journal:  FEBS Lett       Date:  1993-11-29       Impact factor: 4.124

4.  Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression.

Authors:  D T Chalmers; T W Lovenberg; E B De Souza
Journal:  J Neurosci       Date:  1995-10       Impact factor: 6.167

5.  Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor.

Authors:  J Gulyas; C Rivier; M Perrin; S C Koerber; S Sutton; A Corrigan; S L Lahrichi; A G Craig; W Vale; J Rivier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

6.  Mediation of corticotropin releasing factor type 1 receptor phosphorylation and desensitization by protein kinase C: a possible role in stress adaptation.

Authors:  Richard L Hauger; J Alberto Olivares-Reyes; Sandra Braun; Kevin J Catt; Frank M Dautzenberg
Journal:  J Pharmacol Exp Ther       Date:  2003-05-06       Impact factor: 4.030

7.  Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling.

Authors:  A Rühmann; A K Köpke; F M Dautzenberg; J Spiess
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

8.  Promoter analysis of human corticotropin-releasing factor (CRF) type 1 receptor and regulation by CRF and urocortin.

Authors:  Kelly L Parham; Sevasti Zervou; Emmanouil Karteris; Rob D Catalano; Robert W Old; Edward W Hillhouse
Journal:  Endocrinology       Date:  2004-05-13       Impact factor: 4.736

9.  Cell-type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: phospholipase C-mediated responses in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells.

Authors:  Frank M Dautzenberg; Eric Gutknecht; Ilse Van der Linden; J Alberto Olivares-Reyes; Franz Dürrenberger; Richard L Hauger
Journal:  Biochem Pharmacol       Date:  2004-11-01       Impact factor: 5.858

10.  Cloning and characterization of human urocortin.

Authors:  C J Donaldson; S W Sutton; M H Perrin; A Z Corrigan; K A Lewis; J E Rivier; J M Vaughan; W W Vale
Journal:  Endocrinology       Date:  1996-05       Impact factor: 4.736

View more
  9 in total

1.  Desensitization of human CRF2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment.

Authors:  Richard L Hauger; J Alberto Olivares-Reyes; Sandra Braun; Judith Hernandez-Aranda; Christine C Hudson; Eric Gutknecht; Frank M Dautzenberg; Robert H Oakley
Journal:  Regul Pept       Date:  2013-06-29

Review 2.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

Review 3.  Region-specific roles of the corticotropin-releasing factor-urocortin system in stress.

Authors:  Marloes J A G Henckens; Jan M Deussing; Alon Chen
Journal:  Nat Rev Neurosci       Date:  2016-09-02       Impact factor: 34.870

Review 4.  Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.

Authors:  Richard L Hauger; Victoria Risbrough; Robert H Oakley; J Alberto Olivares-Reyes; Frank M Dautzenberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

5.  Dopamine D1 and corticotrophin-releasing hormone type-2α receptors assemble into functionally interacting complexes in living cells.

Authors:  J Fuenzalida; P Galaz; K A Araya; P G Slater; E H Blanco; J M Campusano; F Ciruela; K Gysling
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

6.  Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness.

Authors:  Ariadne Androulidaki; Erini Dermitzaki; Maria Venihaki; Effie Karagianni; Olga Rassouli; Erini Andreakou; Christos Stournaras; Andrew N Margioris; Christos Tsatsanis
Journal:  Mol Cancer       Date:  2009-06-02       Impact factor: 27.401

7.  Anxiolytic-like effects of antisauvagine-30 in mice are not mediated by CRF2 receptors.

Authors:  Eric P Zorrilla; Amanda J Roberts; Jean E Rivier; George F Koob
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

Review 8.  Endocrinology and the brain: corticotropin-releasing hormone signaling.

Authors:  Carolina Inda; Natalia G Armando; Paula A Dos Santos Claro; Susana Silberstein
Journal:  Endocr Connect       Date:  2017-07-14       Impact factor: 3.335

9.  Human corticotrophin releasing factor inhibits cell proliferation and promotes apoptosis through upregulation of tumor protein p53 in human glioma.

Authors:  Yan Feng; Liqun Wang; Xin Liu; Qiang Wu; Haofeng Zhang; Fuguang Hu; Xiaofeng Sun
Journal:  Oncol Lett       Date:  2018-04-02       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.